Kymera Therapeutics, Inc. announced on October 24, 2024, that it recently initiated dosing in the Phase 1 clinical trial in the U.S. evaluating KT-621. KT-621 is a potent, selective, oral degrader of STAT6, administered to adult healthy volunteers.
This milestone marks KT-621 as the first oral STAT6 targeted medicine to advance into the clinic, demonstrating Kymera’s drug discovery capabilities in addressing previously undrugged disease-causing proteins. The company expects to report Phase 1 data in the first half of 2025.
The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered KT-621. The study includes double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, aiming to provide biologic-like activity for patients with allergic and atopic diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.